

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (currently amended) A monomeric, cyclic peptide analogue of a B-chain of a relaxin superfamily member protein which binds to a biological target of the relaxin superfamily protein, and modulates an activity of the biological target, wherein the relaxin superfamily protein is selected from insulin, IGF-I, IGF-II, relaxin 1, relaxin 2, relaxin 3, INSL3, INSL4, INSL5 and INSL6, the biological target being selected from insulin receptors, IGFR-I, IGFR-II, LGR7 and LGR8 and wherein the analogue is produced by modification of a turn or loop moiety of the B-chain of the relaxin superfamily protein, the modification involving selection of at least a first and a second amino acid residue with an alpha-helix or beta-strand carbon separation distance of less than six angstroms and cross-linking the first and second amino acids, wherein the cross-link conformationally constrains the analogue.

2. (canceled)

3. (currently amended) The analogue according to claim 1 or claim 2, wherein the analogue is an INSL3 B-chain analogue modified from a sequence set forth in SEQ ID NO:7.

4. (withdrawn) The analogue according to claim 3, wherein the INSL3 analogue is constrained by a cross-link between a first amino acid within a range of positions 2 and 8 and a second amino acid within a range of positions 21 and 26 of the sequence set forth in SEQ ID NO:7.

5.-6. (canceled)

7. (withdrawn-currently amended) The analogue according to claim 1-~~or~~
~~claim 2~~, which is a relaxin analogue modified from a relaxin-1, relaxin-2, or relaxin-3 B-chain
sequence set forth in SEQ ID NOs:1, 2 and 3, respectively.

8. (withdrawn) The analogue according to claim 7, wherein the relaxin
analogue is constrained by a cross-link between a first amino acid within a range of positions 2
and 8 and a second amino acid within a range of positions 21 and 26 of the sequence set forth in
SEQ ID NO:2.

9. (canceled)

10. (withdrawn-currently amended) The analogue according to claim [[2]] 1,
wherein the first and/or second amino acids are substituted with alternative amino acids suitable
for cross-linking.

11. (withdrawn) The analogue according to claim 10 wherein at least one of
the alternative amino acids is a cysteine residue.

12. (withdrawn) The analogue according to claim 11 wherein both of the
alternative amino acid residues are cysteine residues.

13. (withdrawn) The analogue according to claim 12 wherein the analogue is
cross-linked by oxidizing the cysteine residues to form a disulfide bond between the cysteine
residues.

14. (withdrawn-currently amended) An analogue according to ~~any one of~~
~~claims 1 to 13~~ claim 1, wherein one or more amino acids within the INSL3 or relaxin peptide

analogue sequence, other than the cross-linked first and second amino acids, is optionally substituted to modify one or more biological activities of the analogue.

15. (withdrawn-currently amended) The analogue according to any one of claims 1 to 14, claim 1 wherein the biological target of the analogue is LGR7 and/or LGR8.

16. (withdrawn) The analogue according to claim 15, wherein activity of the biological target is initiated, up-regulated, down-regulated or otherwise blocked.

17. (withdrawn-currently amended) The analogue of any of the preceding claims claim 1, wherein the analogue is conjugated to an A-chain of a relaxin superfamily protein.

18. (withdrawn-currently amended) The analogue according to claim 17, wherein the A-chain of the relaxin superfamily protein is a corresponding A-chain for derived from the relaxin superfamily protein from which the B chain analogue is derived.

19. (withdrawn-currently amended) The analogue according to any one of claims 1 to 18, claim 1, wherein the analogue is conjugated to a reporter group.

20. (withdrawn) The analogue according to claim 19, wherein the reporter group is a radiolabel.

21. (withdrawn) The analogue according to claim 19, wherein the reporter group is a fluorescent label.

22. (withdrawn) The analogue according to claim 19, wherein the reporter group is an enzyme.

23. (withdrawn) The analogue according to claim 19, wherein the reporter group is a carrier.

24.-31. (canceled)

32. (withdrawn, currently amended) A pharmaceutical composition including one or more of the analogues as defined in any one of claims 1 to 23, claimed in claim 1, or pharmaceutically acceptable salts thereof.

33. (withdrawn) The pharmaceutical compositions according to claim 32, further comprising at least one pharmaceutically acceptable carrier or diluent.

34.-49 (canceled)

50. (new) The analogue according to claim 1, wherein the analogue is an INSL3 analogue with the sequence and structure:

TPCMREKLSGHFVRALVRVSGGPCWS

51. (new) The analogue according to claim 1, wherein the analogue is an INSL3 analogue with the sequence and structure:

TPCMREKLSGRHFVRALVRVSGGPCWS

52. (new) The analogue according to claim 1, wherein the analogue is a relaxin analogue with the sequence and structure:

SCMEEVIKLSGRELVRAQIAISGCS